Ocugen Past Earnings Performance

Past criteria checks 0/6

Ocugen's earnings have been declining at an average annual rate of -31.8%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 22.6% per year.

Key information

-31.8%

Earnings growth rate

68.9%

EPS growth rate

Biotechs Industry Growth14.2%
Revenue growth rate-22.6%
Return on equity-129.3%
Net Marginn/a
Last Earnings Update30 Sep 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Ocugen makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

BUL:2H51 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 230-76340
30 Jun 230-83330
31 Mar 230-80330
31 Dec 220-81350
30 Sep 220-74360
30 Jun 220-63320
31 Mar 220-69290
31 Dec 210-58230
30 Sep 210-48180
30 Jun 210-47150
31 Mar 210-38100
31 Dec 200-3480
30 Jun 200-3081
31 Mar 200-187-3
31 Dec 190-2060
30 Sep 190-3969
30 Jun 190-1864
31 Mar 190-19611
31 Dec 180-18610

Quality Earnings: 2H51 is currently unprofitable.

Growing Profit Margin: 2H51 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2H51 is unprofitable, and losses have increased over the past 5 years at a rate of 31.8% per year.

Accelerating Growth: Unable to compare 2H51's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2H51 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.2%).


Return on Equity

High ROE: 2H51 has a negative Return on Equity (-129.33%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/02/28 19:43
End of Day Share Price 2023/12/01 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ocugen, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kristen KluskaCantor Fitzgerald & Co.
Daniil GataulinChardan Capital Markets, LLC
Swayampakula RamakanthH.C. Wainwright & Co.